08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

TxBCardio immunoturbidimetric regulatory update

Corgenix and partner Randox announced the submission of a 510(k) application to FDA for the TxBCardio immunoturbidimetric (IT) assay for use with automated chemistry analyzers to determine aspirin effect in apparently healthy individuals. Corgenix developed...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Corgenix Medical Corp. sales and marketing update

Corgenix's AspirinWorks Test received a 28% reimbursement increase from CMS to $30.92 in 2011 from $25.95 in 2010. Corgenix markets the ELISA test to determine levels of 11-dehydro thromboxane B2 in urine to determine...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

AspirinWorks: Additional Phase III data

A subgroup analysis of 3,261 aspirin-treated patients in the double-blind, placebo-controlled, international Phase III CHARISMA trial showed that patients with the highest quartile concentration of urine 11-dehydro thromboxane B2 had a 66% increased risk for...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Company News

Corgenix Medical Corp., Randox Laboratories deal

Corgenix and Randox will adapt Corgenix's AspirinWorks test for use with automated chemistry analyzers. Randox will manufacture the test, and the companies will share global distribution rights. The test is approved in the U.S....
08:00 , Feb 4, 2008 |  BC Week In Review  |  Company News

Corgenix Medical Corp., Quest Diagnostics sales and marketing update

Quest will offer Corgenix' AspirinWorks test to physicians and laboratories. The test determines the effectiveness of aspirin therapy in reducing the risk of heart attack and stroke. Corgenix acquired rights to the ELISA test...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Clinical News

AspirinWorks regulatory update

FDA granted 510(k) clearance for the AspirinWorks test to help determine the effectiveness of aspirin therapy in reducing the risk of heart attack and stroke. CONX acquired rights to the ELISA test kit, which is...
07:00 , Mar 12, 2007 |  BC Week In Review  |  Company News

Corgenix Medical Corp., Creative Clinical Concepts Inc. deal

CONX acquired rights to Creative Clinical Concept's AspirinWorks business for an undisclosed sum. Creative Clinical Concepts is now eligible for milestones and royalties. Under a 2004 deal, the companies had agreed to shared expenses...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Clinical News

AspirinWorks regulatory update

CONX submitted a 510(k) application to the FDA for AspirinWorks, an ELISA test determines levels of 11-dehydro thromboxane B2 in urine. The kit is used to measure an individual's response to doses of aspirin Corgenix...